TW202345870A - 具有延長半衰期之信使核糖核酸 - Google Patents

具有延長半衰期之信使核糖核酸 Download PDF

Info

Publication number
TW202345870A
TW202345870A TW112111277A TW112111277A TW202345870A TW 202345870 A TW202345870 A TW 202345870A TW 112111277 A TW112111277 A TW 112111277A TW 112111277 A TW112111277 A TW 112111277A TW 202345870 A TW202345870 A TW 202345870A
Authority
TW
Taiwan
Prior art keywords
seq
mrna
nucleic acid
utr
acid sequence
Prior art date
Application number
TW112111277A
Other languages
English (en)
Chinese (zh)
Inventor
大衛 瑞德
麥可 亞伯特 基默
Original Assignee
美商現代公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商現代公司 filed Critical 美商現代公司
Publication of TW202345870A publication Critical patent/TW202345870A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW112111277A 2022-03-25 2023-03-24 具有延長半衰期之信使核糖核酸 TW202345870A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263323748P 2022-03-25 2022-03-25
US63/323,748 2022-03-25
US202263405142P 2022-09-09 2022-09-09
US63/405,142 2022-09-09
US202263419924P 2022-10-27 2022-10-27
US63/419,924 2022-10-27

Publications (1)

Publication Number Publication Date
TW202345870A true TW202345870A (zh) 2023-12-01

Family

ID=86330236

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112111277A TW202345870A (zh) 2022-03-25 2023-03-24 具有延長半衰期之信使核糖核酸

Country Status (6)

Country Link
US (1) US20250313830A1 (enExample)
EP (1) EP4499850A2 (enExample)
JP (1) JP2025510777A (enExample)
CN (1) CN119234042A (enExample)
TW (1) TW202345870A (enExample)
WO (1) WO2023183550A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118542697B (zh) * 2024-05-13 2025-07-08 广州万方健医药有限公司 性生活使用后的避孕套在同时采集和/或检测男性和女性生殖道病原体中的应用
WO2026085234A1 (en) * 2024-10-18 2026-04-23 Modernatx, Inc. 3' untranslated region sequences for extending messenger ribonucleic acids half-life

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CA3174553A1 (en) * 2020-03-05 2021-09-10 Flagship Pioneering Innovations Vi, Llc Host defense suppressing methods and compositions for modulating a genome
EP4158005A1 (en) * 2020-06-01 2023-04-05 ModernaTX, Inc. Phenylalanine hydroxylase variants and uses thereof
WO2021248008A1 (en) * 2020-06-05 2021-12-09 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections
EP4168556A2 (en) * 2020-06-23 2023-04-26 ModernaTX, Inc. Lnp compositions comprising mrna therapeutics with extended half-life

Also Published As

Publication number Publication date
JP2025510777A (ja) 2025-04-15
US20250313830A1 (en) 2025-10-09
EP4499850A2 (en) 2025-02-05
WO2023183550A3 (en) 2023-11-09
CN119234042A (zh) 2024-12-31
WO2023183550A2 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
EP3852728B1 (en) Preparation of lipid nanoparticles and methods of administration thereof
EP3917503B1 (en) Methods of preparing lipid nanoparticles
JP2023055716A (ja) Ｉｉ型シトルリン血症の治療のためのシトリンをコードするポリヌクレオチド
AU2021212262A1 (en) Methods of preparing lipid nanoparticles
AU2018326799A1 (en) Methods of making lipid nanoparticles
US20230242908A1 (en) Lnp compositions comprising mrna therapeutics with extended half-life
JP2021504343A (ja) 尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド
US20220251577A1 (en) Endonuclease-resistant messenger rna and uses thereof
JP2021504335A (ja) フェニルケトン尿症の治療用のフェニルアラニンヒドロキシラーゼをコードするポリヌクレオチド
TW202345870A (zh) 具有延長半衰期之信使核糖核酸
EP3773745A1 (en) Messenger rna comprising functional rna elements
US20250213664A1 (en) Mrnas encoding checkpoint cancer vaccines and uses thereof
CA3158013A1 (en) Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease